Hondra-sila

General characteristics. Structure:

Active ingredient: chondroitin sulfate;

100 g of ointment contain chondroitin of sodium of sulfate 5 g in terms of 100% substance;

excipients: a dimethyl sulfoxide, lanolin, paraffin white soft, the water purified.

Pharmacological properties:

Chondroitin sulfate renders the hondroprotektorny, hondrostimuliruyushchy, regenerating, antiinflammatory and anesthetizing action. Improves phosphorus-calcium exchange in cartilaginous tissue, inhibits the enzymes breaking structure and function of a joint cartilage, slows down processes of a degeneration of cartilaginous tissue. Stimulates synthesis of glucosaminoglycans, normalizes metabolism of hyaline cartilaginous tissue, promotes regeneration of cartilaginous surfaces and a joint bag. At external use drug slows down progressing of an osteoarthrosis, reduces an inflammation and pain in the affected joints.

The dimethyl sulfoxide which is a part of drug promotes the best penetration of chondroitin through skin.

The sulfate chondroitin pharmacokinetics at cutaneous use is not investigated. At cutaneous application of drug its maximum concentration in a blood plasma is reached in 3-4 hours, in synovial fluid – in 4-5 hours after use. Bioavailability – 13%. It is removed by kidneys within 24 hours.

Indications to use:

Degenerative and dystrophic diseases of joints and backbone (preferential localized forms): osteoarthrosis, osteochondrosis.

Route of administration and doses:

Drug is used outwardly. To apply ointment 2–3 times a day with a thin layer on skin in the field of defeat, easily rubbing before full absorption.

Duration of a course of treatment is defined individually depending on efficiency and portability of therapy and, as a rule, makes 2–3 weeks. If necessary to repeat a course.

Features of use:

Use during pregnancy or feeding by a breast.

Safety and efficiency of use of drug during pregnancy or feeding by a breast are not established therefore it is possible to use drug only in that case when according to the doctor, the advantage at use exceeds risk.

Ability to influence speed of response at control of motor transport or work with other mechanisms.

Does not influence.

Children.

Drug should not be used for treatment of children due to the lack of sufficient clinical experience.

Side effects:

Skin allergic reactions: an itch, a hyperemia, burning, rash which can arise in sites of application.

Interaction with other medicines:

At cutaneous use of drug its interaction with other medicines is not established.

Contraindications:

Individual hypersensitivity to drug components. Thrombophlebitis, tendency to bleeding, acute inflammatory processes on the site of putting drug.
Appropriate security measures at use.

Drug should be applied only on the unimpaired sites of skin, it is necessary to avoid hit of drug on open wounds, in eyes and on mucous membranes.

Overdose:

Cases of overdose are not described. Hypersensitivity chances which demand drug withdrawal and performing symptomatic therapy.

Storage conditions:

Period of validity. 3 years. Not to use drug after the termination of the period of validity specified on packaging. To store in the place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

On 30 g in a tuba. On 1 tuba in a pack.